Corporate Profile
Our purpose is guided by an unwavering commitment to the communities we serve as we discover and advance novel therapies for debilitating diseases and conditions with high, often underrecognized, unmet medical needs. We explore scientific approaches tailored to diseases and conditions where we believe we can make the greatest difference. Our approach is not limited to any single condition, disease, or modality and is rooted in understanding the underlying biological drivers to advance meaningful progress in how diseases and conditions are understood and treated.
Our team brings to Amylyx collective expertise from therapeutic development through commercialization across numerous diseases, which serves as a critical foundation for tackling some of medicine’s toughest challenges.
Today, we are focused on our four investigational therapies across several diseases: avexitide in post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI), AMX0035 in Wolfram syndrome, AMX0114 in amyotrophic lateral sclerosis (ALS), and AMX0318 in PBH and other rare diseases.
Minimum 15 minutes delayed. Source: LSEG